Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
In advance of Tuesday’s hearing on MannKind Corporation’s inhaled insulin, the US FDA has outlined several safety and efficacy issues of potential concern that it will ask its Endocrinologic and Metabolic Drugs Advisory Committee to address, leading up to a vote on approval.
The product, Technosphere inhaled insulin system (Afrezza), consists of a premeal insulin powder loaded into a cartridge for oral inhalation. The company is seeking an indication as an ultra-rapid-acting insulin for adults with type 1 or 2 diabetes. In type 1 patients, the indication would be for use with injected basal insulin.
Briefing documents from both MannKind Corporation and the FDA were posted Friday on the FDA website.
According to MannKind Corporation, the inhaled insulin, which is composed of recombinant human insulin and an inert excipient, has a more rapid onset and shorter duration of action than current injectable insulins, and therefore "more closely mimics mealtime endogenous insulin secretion."
However, the FDA has declined to approve two previous versions of the product that used different inhalers (in 2010 and 2011).
http://www.medscape.com/viewarticle/822809
(free registration)
The product, Technosphere inhaled insulin system (Afrezza), consists of a premeal insulin powder loaded into a cartridge for oral inhalation. The company is seeking an indication as an ultra-rapid-acting insulin for adults with type 1 or 2 diabetes. In type 1 patients, the indication would be for use with injected basal insulin.
Briefing documents from both MannKind Corporation and the FDA were posted Friday on the FDA website.
According to MannKind Corporation, the inhaled insulin, which is composed of recombinant human insulin and an inert excipient, has a more rapid onset and shorter duration of action than current injectable insulins, and therefore "more closely mimics mealtime endogenous insulin secretion."
However, the FDA has declined to approve two previous versions of the product that used different inhalers (in 2010 and 2011).
http://www.medscape.com/viewarticle/822809
(free registration)